Eli Lilly looks to extend its winning streak over the broader market to 6 years

Eli Lilly looks to extend its winning streak over the broader market to 6 years


An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. 

Shelby Knowles | Bloomberg | Getty Images

Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question.



Source

Anne Wojcicki has a new offer to take 23andMe private, this time for .7 million
Health

Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million

Anne Wojcicki attends the WSJ Magazine Style & Tech Dinner in Atherton, California, on March 15, 2023. Kelly Sullivan | Getty Images Entertainment | Getty Images 23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the embattled genetic testing company private, according to a Friday filing with the U.S. Securities […]

Read More
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Health

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Sopa Images | Lightrocket | Getty Images Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money. […]

Read More
Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says
Health

Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters The long-running U.S. shortage of Novo Nordisk‘s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said on Friday.  The FDA’s decision will threaten the […]

Read More